Pharmaceutical supply chains face persistent supply-demand imbalances driven by global demand for metabolic therapies. Drug manufacturers are allocating billions toward dedicated contract manufacturing capacity.
Infrastructure Investment
Contract Development and Manufacturing Organizations are expanding specialized cold-chain logistics networks. Market projections indicate capacity bottlenecks will persist through mid-2026 despite heavy capital expenditure.